ClinicalTrials.gg
CompletedNCT04704531PRO-037Updated Mar 3, 2026Results posted

Phase II Clinical Study to Evaluate the Efficacy of Multidose Lagricel® Ofteno Ophthalmic Solution as Treatment for Dry Eye Disease.

A Phase 2 interventional study of Sodium Hyaluronate Ophthalmic 0.4% one drop twice a day (BID) and Sodium Hyaluronate Ophthalmic 0.4% one drop four times a day (QID) in Dry Eye, sponsored by Laboratorios Sophia S.A de C.V.. Completed at 1 site in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-03.

Sponsored by Laboratorios Sophia S.A de C.V. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
141
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Dry Eye Syndromes by Laboratorios Sophia S.A de C.V. — 2 open to participants now, 2 under way, none of them phase 3. Dry Eye Syndromes · Laboratorios Sophia S.A de C.V..

Enrollment
4th of 13
141 · median 34
Started
2022
the only one that year
Phase 2
2 of 13
none open now
Registered
9th of 13
by date

Among the 13 studies in Dry Eye Syndromes by Laboratorios Sophia S.A de C.V., this one is the 4th largest by enrollment, is the only one that started in 2022, is one of 2 in phase 2, and was the 9th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

2 of the 13 studies in Dry Eye Syndromes by Laboratorios Sophia S.A de C.V. are open now. Recruiting first, the newest first:

All 2 open studies →

Where they have run

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Dry Eye Syndromes by Laboratorios Sophia S.A de C.V., or all of them as a file.
02

Study summary

Phase II, comparative, controlled, multicenter, parallel group, open, randomized clinical study. The main outcome variable will be the Ocular Surface Disease Index (OSDI) questionnaire. Three dosage schemes of topical ophthalmic application of Multidose Lagricel® Ofteno (Sodium Hyaluronate 0.4%; preservative free) are to be evaluated in patients diagnosed with mild to severe dry eye. Each group will be exposed to one of the following administration schemes: 1 drop bis in die (BID), 1 drop quater in die (QID), or 1 drop six times per day; instillation will take place in both eyes (OU).

03

Conditions studied

  • Dry Eye

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years old.
  • Being capable of voluntarily grant a signed .
  • Being willing and able to meet the requirements of the study such as attending programmed visits, treatment plan and other study procedures.
  • Women in child-bearing age must assure the continuation (start ≥ 30 days prior to informed consent signing) of a hormonal method or intrauterine device (IUD) during the study.
  • Presenting a mild to moderate dry eye disease diagnosis, defined as:

    • OSDI score between 13 and 32, plus one of the following:

      • More than 5 dots of corneal staining
      • More than 9 dots of conjunctival staining
      • Tear Break-up Time (BUT) \< 10 seconds

Exclusion criteria

Exclusion Criteria:

  • Pregnancy, breastfeeding or planning to become pregnant during the time of the study
  • Having participated in clinical trials within 30 days prior to signing this study's form.
  • Having participated previously in this study.
  • Best Corrected Visual Acuity (BCVA) equal or worse than 20/200, in either eye.
  • Diagnosis of any of the following:

    • Allergic, viral or bacterial conjunctivitis
    • Anterior blepharitis
    • Parasite infestation of ocular structures (Demodex, for example)
    • Unresolved history of ocular trauma
    • Scarring diseases of the ocular surface
    • Corneal or conjunctival ulcers
    • Filamentary keratitis
    • Neurotrophic keratitis
    • Bullous keratopathy
    • Neoplastic diseases of the ocular surface or ocular annexes
    • Diseases presenting fibrovascular proliferations on the corneal or conjunctival surface.
    • Any retinal or posterior segment diseases that require treatment or threat the visual outcome.
    • Glaucoma
  • Requiring management for dry eye that includes implementation of treatments described in the step 2 management recommendations of the Tear Film \& Ocular Surface Society's Dry Eye Work Shop II (TFO DEWS II).
  • Previous history of drug addiction within the last 2 years prior to signing this study's informed consent form.
  • Having a previous history of any ophthalmological surgical procedure, within the last 3 months prior to the informed consent signing date.
  • Being a contact lens user, rigid or soft. Inclusion is possible if the use of contact lenses is suspended both during the study period and at least 15 days prior inclusion takes place.
  • Previous history of any medical affliction, acute or chronic, that according to the investigator may increase either the risk to the patient for participating in this study or the risk of interference of the accurate interpretation of results.
  • Known to any of the components of the products used in this study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
141 participants (actual)

Study arms

  • Experimental
    Group 1

    Application of one drop of Multidose Lagricel® Ofteno (Sodium Hyaluronate 0.4%) one drop twice a day (BID) in both eyes (OU) during 30 days.

    Drug: Sodium Hyaluronate Ophthalmic 0.4% one drop twice a day (BID)

  • Experimental
    Group 2

    Application of one drop of Multidose Lagricel® Ofteno (Sodium Hyaluronate 0.4%) one drop four times a day (QID) in both eyes (OU) during 30 days.

    Drug: Sodium Hyaluronate Ophthalmic 0.4% one drop four times a day (QID)

  • Experimental
    Group 3

    Application of one drop of Multidose Lagricel® Ofteno (Sodium Hyaluronate 0.4%) 6 times per day in OU during 30 days.

    Drug: Sodium Hyaluronate Ophthalmic 0.4% Six times per day

Interventions

  • DrugSodium Hyaluronate Ophthalmic 0.4% one drop twice a day (BID)

    Topical ophthalmic administration of one drop of Multidose Lagricel® Ofteno BID.

    Also known as: PRO-037, Lagricel® Ofteno

  • DrugSodium Hyaluronate Ophthalmic 0.4% one drop four times a day (QID)

    Topical ophthalmic administration of one drop of Multidose Lagricel® Ofteno QID.

    Also known as: PRO-037, Lagricel® Ofteno

  • DrugSodium Hyaluronate Ophthalmic 0.4% Six times per day

    Topical ophthalmic administration of one drop of Multidose Lagricel® Ofteno six times per day.

    Also known as: PRO-037, Lagricel® Ofteno

06

What researchers measure

Primary outcomes

  1. Change in Ocular Surface Disease Index (OSDI)

    OSDI is a questionnaire designed to measure eye surface irritation with Rasch analysis to produce estimates on a linear interval scale. The OSDI score ranges from 0 to 100, with higher scores indicating greater severity of symptoms. A score of 0 represents no symptoms, while 100 represents the most severe symptoms.

    Time frame: Basal Visit (BV) (day 0) and Final Visit (FV) (day 31+1,).

  2. Incidence of Adverse Events (AE)

    Presence/absence adverse events, defined as the appearance of any unfavorable reaction in a patient participating in a clinical investigation in which any pharmaceutical product is being administered, regardless of the causal attribution and whether it was considered related or not to the investigation products.

    Time frame: Up to Day 33 (+ 1) (safety call).

Secondary outcomes

  1. Change in Tear Break-up Time (BUT)

    After application of fluorescein stain, using a slit lamp and its cobalt blue filter, the time elapsed after instructing the patient to blink 1 or 2 times and the appearance of dry spots on the ocular surface will be counted and reported as BUT. Normally, this parameter is ≥ 10 seconds.

    Time frame: Baseline Visit (BV) (day 0,), Fisrt follow-up visit (V1) (day 15±1), and Final Visit (FV) (day 31+1).

  2. Change in Conjunctival and Corneal Staining With Lissamine Green

    The evaluation will take place after applying the lissamine green stain on the ocular surface and evaluating the resulting staining pattern. This will be measured through the Oxford scale which includes 6 grades: Absent (0), Minimal (I), Mild (II), Moderate (III), Marked (IV), Severe (V).

    Time frame: Baseline Visit (BV) (day 0,), Fisrt follow-up visit (V1) (day 15±1), and Final Visit (FV) (day 31+1).

  3. Change in Conjunctival and Corneal Staining With Fluorescein

    The evaluation will take place after applying the fluorescein stain on the ocular surface and evaluating the resulting staining pattern. This will be measured through the Oxford scale which includes 6 grades: Absent (0), Minimal (I), Mild (II), Moderate (III), Marked (IV), Severe (V).

    Time frame: Baseline Visit (BV) (day 0,), Fisrt follow-up visit (V1) (day 15±1), and Final Visit (FV) (day 31+1).

  4. Change in Conjunctival Hyperemia

    Rate of conjunctival hyperemia will be evaluated through the Efron scale which includes 5 grades: Normal (0), Very Mild (I), Mild (II), Moderate (III), and Severe (IV).

    Time frame: Baseline Visit (BV) (day 0,), Fisrt follow-up visit (V1) (day 15±1), and Final Visit (FV) (day 31+1).

  5. Incidence of Chemosis

    Chemosis will be evaluated as present (if conjunctiva separates from the sclera in ≥ 1/3 of the palpebral opening area or if it exceeds the eyelid's gray line) or absent. This evaluation will be made taking in consideration the counts of "absent" seen per counts of eyes and per visit.

    Time frame: Baseline Visit (BV) (day 0,), Fisrt follow-up visit (V1) (day 15±1), and Final Visit (FV) (day 31+1).

  6. Change in Best Corrected Visual Acuity (BCVA)

    With the patient's best possible refractive correction, visual acuity will be evaluated through the Snellen chart. Its notation (fraction or decimal) is described as the distance from the chart at which the test is performed, divided by the distance at which a letter equals vertically 5 minutes of arc. The normal score for a VA is 20/20.This score is expressed in decimal (i.e. 1.0) format. In decimal format, a lower number is a worse outcome.

    Time frame: Baseline Visit (BV) (day 0,), Fisrt follow-up visit (V1) (day 15±1), and Final Visit (FV) (day 31+1).

  7. Change in Intraocular Pressure (IOP)

    Measured through Goldman tonometer in milligrams of mercury (mmHg). After instillation of topical anesthetic (tetracaine 0.5%) and fluorescein stain, IOP will be evaluated. Normal values are considered between 10 and 21 mmHg.

    Time frame: BV (day 0, baseline visit), V1 (day 15±1, first follow-up visit), and FV (day 31+1, final visit).

07

Results

Posted Mar 3, 2026

Participant flow

Participant flow — Overall Study
MilestoneGroup 1Group 2Group 3
Started474747
Completed454546
Not completed221

Outcome measures

PrimaryChange in Ocular Surface Disease Index (OSDI)

OSDI is a questionnaire designed to measure eye surface irritation with Rasch analysis to produce estimates on a linear interval scale. The OSDI score ranges from 0 to 100, with higher scores indicating greater severity of symptoms. A score of 0 represents no symptoms, while 100 represents the most severe symptoms.

Time frame:
Basal Visit (BV) (day 0) and Final Visit (FV) (day 31+1,).
Reported as:
Mean · score on a scale
Change in Ocular Surface Disease Index (OSDI)
score on a scaleGroup 1Group 2Group 3
BV25.8 ± 4.925.8 ± 4.724.8 ± 5.3
FV12.8 ± 6.012.2 ± 5.811.9 ± 6.9
PrimaryIncidence of Adverse Events (AE)

Presence/absence adverse events, defined as the appearance of any unfavorable reaction in a patient participating in a clinical investigation in which any pharmaceutical product is being administered, regardless of the causal attribution and whether it was considered related or not to the investigation products.

Time frame:
Up to Day 33 (+ 1) (safety call).
Reported as:
Number · adverse events
Incidence of Adverse Events (AE)
adverse eventsGroup 1Group 2Group 3
Related and unexpected AE241722
Related and expected AE1197
Non-related AE211516
SecondaryChange in Tear Break-up Time (BUT)

After application of fluorescein stain, using a slit lamp and its cobalt blue filter, the time elapsed after instructing the patient to blink 1 or 2 times and the appearance of dry spots on the ocular surface will be counted and reported as BUT. Normally, this parameter is ≥ 10 seconds.

Time frame:
Baseline Visit (BV) (day 0,), Fisrt follow-up visit (V1) (day 15±1), and Final Visit (FV) (day 31+1).
Reported as:
Mean · seconds
Change in Tear Break-up Time (BUT)
secondsGroup 1Group 2Group 3
BV6.1 ± 2.26.4 ± 2.16.3 ± 2.3
V19.1 ± 3.39.0 ± 2.59.2 ± 2.8
FV9.7 ± 3.410.1 ± 3.211.0 ± 4.3
SecondaryChange in Conjunctival and Corneal Staining With Lissamine Green

The evaluation will take place after applying the lissamine green stain on the ocular surface and evaluating the resulting staining pattern. This will be measured through the Oxford scale which includes 6 grades: Absent (0), Minimal (I), Mild (II), Moderate (III), Marked (IV), Severe (V).

Time frame:
Baseline Visit (BV) (day 0,), Fisrt follow-up visit (V1) (day 15±1), and Final Visit (FV) (day 31+1).
Reported as:
Number · Eyes (right)
Change in Conjunctival and Corneal Staining With Lissamine Green
Eyes (right)Group 1Group 2Group 3
BV Conjunctival and corneal staining with lissamine green : Absent (0)151514
BV Conjunctival and corneal staining with lissamine green : Minimal(I)211921
BV Conjunctival and corneal staining with lissamine green : Mild (II)91010
BV Conjunctival and corneal staining with lissamine green : Moderate (III)011
V1 Conjunctival and corneal staining with lissamine : Absent (0)283031
V1 Conjunctival and corneal staining with lissamine : Minimal(I)151415
V1 Conjunctival and corneal staining with lissamine : Mild (II)210
V1 Conjunctival and corneal staining with lissamine : Moderate (III)000
FV Conjunctival and corneal staining with lissamine : Absent (0)403643
FV Conjunctival and corneal staining with lissamine : Minimal(I)593
FV Conjunctival and corneal staining with lissamine : Mild (II)000
FV Conjunctival and corneal staining with lissamine : Moderate (III)000
SecondaryChange in Conjunctival and Corneal Staining With Fluorescein

The evaluation will take place after applying the fluorescein stain on the ocular surface and evaluating the resulting staining pattern. This will be measured through the Oxford scale which includes 6 grades: Absent (0), Minimal (I), Mild (II), Moderate (III), Marked (IV), Severe (V).

Time frame:
Baseline Visit (BV) (day 0,), Fisrt follow-up visit (V1) (day 15±1), and Final Visit (FV) (day 31+1).
Reported as:
Number · Eyes (right)
Change in Conjunctival and Corneal Staining With Fluorescein
Eyes (right)Group 1Group 2Group 3
BV Conjunctival and corneal staining with fluorescein : Absent (0)131111
BV Conjunctival and corneal staining with fluorescein : Minimal (I)202225
BV Conjunctival and corneal staining with fluorescein : Mild (II)12119
BV Conjunctival and corneal staining with fluorescein : Moderate (III)011
V1 Conjunctival and corneal staining with fluorescein : Absent (0)202328
V1 Conjunctival and corneal staining with fluorescein : Minimal (I)192117
V1 Conjunctival and corneal staining with fluorescein : Mild (II)611
V1 Conjunctival and corneal staining with fluorescein : Moderate (III)000
FV Conjunctival and corneal staining with fluorescein : Absent (0)283036
FV Conjunctival and corneal staining with fluorescein : Minimal (I)161510
FV Conjunctival and corneal staining with fluorescein : Mild (II)100
FV Conjunctival and corneal staining with fluorescein : Moderate (III)000
SecondaryChange in Conjunctival Hyperemia

Rate of conjunctival hyperemia will be evaluated through the Efron scale which includes 5 grades: Normal (0), Very Mild (I), Mild (II), Moderate (III), and Severe (IV).

Time frame:
Baseline Visit (BV) (day 0,), Fisrt follow-up visit (V1) (day 15±1), and Final Visit (FV) (day 31+1).
Reported as:
Number · Eyes (right)
Change in Conjunctival Hyperemia
Eyes (right)Group 1Group 2Group 3
BV: Normal (0)1167
BV: Very Mild (I)142119
BV: Mild (II)171719
BV: Moderate (III)311
V1: Normal (0)161814
V1: Very Mild (I)212328
V1: Mild (II)844
V1: Moderate (III)000
FV: Normal (0)202124
FV: Very Mild (I)242421
FV: Mild (II)101
FV: Moderate (III)000
SecondaryIncidence of Chemosis

Chemosis will be evaluated as present (if conjunctiva separates from the sclera in ≥ 1/3 of the palpebral opening area or if it exceeds the eyelid's gray line) or absent. This evaluation will be made taking in consideration the counts of "absent" seen per counts of eyes and per visit.

Time frame:
Baseline Visit (BV) (day 0,), Fisrt follow-up visit (V1) (day 15±1), and Final Visit (FV) (day 31+1).
Reported as:
Number · Eyes (right)
Incidence of Chemosis
Eyes (right)Group 1Group 2Group 3
BV: Absent454546
V1: Absent454546
FV: Absent454546
SecondaryChange in Best Corrected Visual Acuity (BCVA)

With the patient's best possible refractive correction, visual acuity will be evaluated through the Snellen chart. Its notation (fraction or decimal) is described as the distance from the chart at which the test is performed, divided by the distance at which a letter equals vertically 5 minutes of arc. The normal score for a VA is 20/20.This score is expressed in decimal (i.e. 1.0) format. In decimal format, a lower number is a worse outcome.

Time frame:
Baseline Visit (BV) (day 0,), Fisrt follow-up visit (V1) (day 15±1), and Final Visit (FV) (day 31+1).
Reported as:
Mean · decimal score
Change in Best Corrected Visual Acuity (BCVA)
decimal scoreGroup 1Group 2Group 3
BV0.97 ± 0.080.99 ± 0.040.98 ± 0.04
V10.98 ± 0.070.99 ± 0.020.99 ± 0.02
FV0.97 ± 0.080.99 ± 0.030.99 ± 0.04
SecondaryChange in Intraocular Pressure (IOP)

Measured through Goldman tonometer in milligrams of mercury (mmHg). After instillation of topical anesthetic (tetracaine 0.5%) and fluorescein stain, IOP will be evaluated. Normal values are considered between 10 and 21 mmHg.

Time frame:
BV (day 0, baseline visit), V1 (day 15±1, first follow-up visit), and FV (day 31+1, final visit).
Reported as:
Mean · mmHg
Change in Intraocular Pressure (IOP)
mmHgGroup 1Group 2Group 3
BV13.7 ± 2.614.5 ± 2.814.4 ± 2.5
V113.6 ± 2.414.1 ± 2.313.6 ± 2.1
FV13.6 ± 2.513.8 ± 2.213.7 ± 2.1

Adverse events

Collected over From day 1 (basal visit) to the safety call on day 33 (±1 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 10/47 (0%)1/47 (2.1%)22/47 (46.8%)
Group 20/47 (0%)0/47 (0%)22/47 (46.8%)
Group 30/47 (0%)0/47 (0%)22/47 (46.8%)
Most frequent serious events
Most frequent serious events
EventGroup 1Group 2Group 3
reaction to immunizationImmune system disorders1/470/470/47
Most frequent other events
Showing 10 of 25
Most frequent other events
EventGroup 1Group 2Group 3
Irritation in the area of instillationEye disorders15/4714/4713/47
abnormal sensation in the eyeEye disorders6/473/474/47
Abormal ocular sensationEye disorders6/473/474/47
PruritusEye disorders2/472/475/47
Blurred visionEye disorders5/474/474/47
presence of product residueProduct Issues2/475/474/47
HeadacheNervous system disorders2/470/474/47
Foreign body sensation in the eyeEye disorders4/473/472/47
TearingEye disorders4/472/471/47
Ocular hyperaemiaEye disorders2/470/471/47

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Group 1Group 2Group 3Total
<=18 years0000
Between 18 and 65 years454544134
>=65 years2237
Age, Continuous
Age, Continuous(years)Group 1Group 2Group 3Total
Mean38.5 ± 14.638.9 ± 13.336.5 ± 14.937.95 ± 14.21
Sex: Female, Male
Sex: Female, Male(Participants)Group 1Group 2Group 3Total
Female32312891
Male15161950
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Group 1Group 2Group 3Total
Count of participants———0
Region of Enrollment
Region of Enrollment(participants)Group 1Group 2Group 3Total
Mexico474747141
Brake up time of the tear film
Brake up time of the tear film(seconds)Group 1Group 2Group 3Total
Mean9.1 ± 3.39.0 ± 2.59.2 ± 2.89.0 ± 3.5
08

Study locations

1 site
  • Instituto Jalisciense del Metabolismo, S.C.
    Guadalajara, Jalisco 44670, Mexico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Jun 2022, 5 months.

Results were first posted in Mar 2026, 3 years 8 months after primary completion.

Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's 5 months is below that.

Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2021
First posted
Jan 11, 2021
StartActual
Jan 3, 2022
Primary completionActual
Jun 8, 2022
CompletionActual
Jun 8, 2022
Results first posted
Mar 3, 2026
Last update
Mar 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04704531
Responsible party
Sponsor
First posted
Jan 11, 2021
Start date
Jan 3, 2022
Primary completion
Jun 8, 2022
Completion
Jun 8, 2022
Results posted
Mar 3, 2026
Last update
Mar 3, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion